Evaluation of Volume Response of Low Grade Glioma to Radiochemotherapy treated for Inoperable Progression or Residual Tumor


Authors: R. Bartoš 1,2;  F. Třebický 3;  A. Malucelli 1,2;  A. Hejčl 1,2;  J. Zárubová 4;  D. Hořínek 1,2;  R. Peter 2;  M. Sameš 1
Authors‘ workplace: Neurochirugická klinika Masarykovy nemocnice, Ústí nad Labem 1;  Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně 2;  Ústav radiační onkologie, Nemocnice Na Bulovce, Praha 3;  Neurologické oddělení, Thomayerova nemocnice, Praha 4
Published in: Cesk Slov Neurol N 2014; 77/110(2): 216-222
Category: Short Communication

Overview

Aim:
Evaluation of low-grade glioma clinical and volume response to concomitant and adjuvant chemo-radiotherapy.

Material and methods:
We describe a series of seven patients (five men and two women) with defined progression or an inoperable residual tumor after low-grade glioma surgery. Tumor volume regression was evaluated by means of manual computer volumetry.

Results:
Using computerized volumetric quantification in our pilot set of patients, we observed mean 90% (73–100%) reduction in tumor volume on T1W MRIs and 73% (41–100%) reduction of tumor volume on T2W MRIs. Following cancer treatment, regression of epileptic seizures occurred in three patients, Jacksonian sensory epileptic seizures stayed stable in one patient.

Conclusion:
Combined cancer treatment in patients with inoperable low-grade glioma WHO grade II with low proliferation activity could lead to substantial tumor volume regression in a significant proportion of patients.

Key words:
low-grade glioma – chemotherapy – radiotherapy – temozolomide – computer volumetry

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manu­script met the ICMJE “uniform requirements” for biomedical papers.


Sources

1. Třebický F, Kubeš J, Bartoš R, Malucelli A, Sameš M et al. Léčba nízkostupňového gliomu supratentoriální oblasti mozku po neurochirurgické subtotální resekci s projevy objemového up‑ gradingu. Klin Onkol 2012; 25(4): 294– 298.

2. Macdonald DR, Cascino TL, Schold SC jr, Cairncross JG.Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8(7): 1277– 1280.

3. Bartoš R, Sameš M, Zolal A, Radovnický T, Hejčl A, Vachata P et al. Resekce insulárních gliomů –  volumetrické hodnocení radikality. Cesk Slov Neurol N 2009; 72/ 105(6): 534– 541.

4. Ricard D, Kaloshi G, Amiel‑ Benouaich A, Lejeune, Marie Y, Mandonnet E et al. Dynamic history of low‑ grade gliomas before and after temozolomide treatment. Ann Neurol 2007; 61(5): 484– 490.

5. Brada M, Viviers L, Abson C, Hines F, Britton J,Ashley S et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003; 14(12): 1715– 1721.

6. Hoang‑ Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J et al. Temozolomide as initial treatment for adults with low‑ grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004; 22(15): 3133– 3137.

7. Kaloshi G, Benouaich‑ Amiel A, Diakite F, Taillibert S,Lejeune J, Laigle‑ Donadey F et al. Temozolomide for low‑ grade gliomas: predictive impact of 1p/ 19q loss on response and outcome. Neurology 2007; 68(21); 1831– 1836.

8. Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ et al. First‑line temozolomide chemotherapy in progressive low‑ grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 2011; 13(2): 235– 241.

9. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 2007; 82(3): 281– 288.

10. Tosoni A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008; 89(2): 179– 185.

11. Pace A, Vidiri A, Galiè E, Carosi M, Telera S, Cianciulli AM et al. Temozolomide chemotherapy for progressive low‑ grade glioma: clinical benefits and radiological response. Ann Oncol 2003; 14(12): 1722– 1726.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 2

2014 Issue 2

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account